Congratulations to Harry Ross and the entire RxKinetix team on the Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) deal. The disclosed terms indicate Endo Pharma will pay a $20M up-front fee and will follow on with up to an additional $95M in clinical development and regulatory milestone payments.
Early indications are that RxKinteix, like Myogen, will remain [...]